Providing search and assessment support for oncology projects
Challenge
A listed North American company needed hands-on support with the identification, assessment and in-licensing of early-stage oncology assets.
Solution
We consulted our industry network to identify a number of high-quality opportunities that had not yet been identified by our client’s in-house business development team. We worked closely with our client’s scientific staff to screen and assess opportunities prior to entering heads of terms, then provided advice on structuring heads of terms, subsequent due diligence and license negotiations.
Related Case Studies
Explore similar engagements and see how we've helped other clients achieve their goals.
Asset Scouting
Scouting for assets discontinued from development due to neutralizing antibodies (Nabs)
Challenge: An early-stage biotech company asked Alacrita to identify drug program assets that had been discontinued from further development due to neutralizing antibodies (Nabs)...
Asset Scouting
Asset scouting for novel injectable formulations for large pharma
Challenge: A public, multi-national pharmaceutical company historically focused on producing generics (including branded), active pharmaceuticals ingredients, biologics, and over...
Asset Scouting
In-Licensing Support and Asset Scouting in CNS
Challenge: An early-stage biotechnology company with several assets in pre-clinical development for CNS diseases wanted to supplement its internal pipeline with external...
Asset Scouting
Scouting for autoimmune / auto-inflammatory assets
Challenge: A pharma company was interested in identifying novel protein-based autoimmune / auto-inflammatory assets early in development from pre-GLP studies to 18 months from an...
Interested in Learning More?
Contact us to discuss how we can support your project with similar expertise.